×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Liver Cancer

Kristie L. Kahl
The Healing Net Foundation gathers patients, caregivers and health care providers to collaborate in raising awareness and educating the medical community about an underserved disease: neuroendocrine tumors.
Katie Kosko
Dana-Farber Cancer Institute opens the first-ever Lynch Syndrome Center to help patients and families with the inherited condition.
Wayne Kuznar
Patients with previously untreated liver cancer, or hepa­tocellular carcinoma (HCC), lived twice as long if they responded to a tyrosine kinase inhibitor, a type of targeted therapy.
Katie Kosko
Researchers call for universal testing after study finds high prevalence of hepatitis B and hepatitis C infections.
Beth Fand Incollingo
The Cholangiocarcinoma Foundation has won a grant from Bayer to create a website and outreach to patients and doctors to let them know that all patients with the disease need to have their tumors sequenced, because there are existing medicines and clinical trials that may help patients with actionable mutations more than the standard of care.
Beth Fand Incollingo
Targeted drugs and immunotherapies are still on the horizon for people with cholangiocarcinoma, or bile duct cancer.
Beth Fand Incollingo
A lot is still unknown about the causes of cholangiocarcinoma, because this type of cancer, which affects the bile ducts inside or outside the liver, is so rare.
Brielle Benyon
Maria Falzone won't let her diagnosis of advanced cholangiocarcinoma stifle her sense of humor.
Katie Kosko
African-Americans who received a racially matched liver had better survival outcomes compared with unmatched patients, according to a review of national data.
Kristie L. Kahl
The Food and Drug Administration approved Cabometyx (cabozantinib) tablets for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with Nexavar (sorafenib).
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

Patient Caregiver Advocate Other